Sector News

Allergan to open R&D site in Kendall Square

January 8, 2019
Life sciences

Allergan is setting up an R&D group in Kendall Square. Headed by Don Frail, the Kendall Square group will work to connect Allergan to venture capital groups and startups in the Cambridge, Massachusetts, hot spot.

Leading drug developers such as AbbVie, Eli Lilly and Pfizer have congregated in Kendall Square to get closer to the many biotechs that call the area home. Allergan has held off on establishing a presence in the location for longer than many of its peers but has now decided to add a Kendall Square site to its R&D network.

Allergan is putting Frail, its senior vice president of research and external scientific innovation and nonclinical and translational sciences, in charge of the site. When the site opens later this quarter, Allergan, like its peers before it, hopes proximity to innovative startups will boost its prospects.

“Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and startups in the area,” Allergan chief R&D officer David Nicholson said in a statement. “I am confident that our new location in Cambridge, along with Don’s deep expertise will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines.”

The creation of the Kendall Square office will allow Frail to relocate back to Massachusetts. Frail was based out of Boston before he joined Allergan and moved to Irvine, California, in 2014. Following the move back to the East Coast, Frail will continue to lead the Irvine team while working out of Kendall Square.

The external scientific innovation and nonclinical and translational sciences team Frail leads will stay back in Irvine, which will remain the focal point of Allergan’s R&D activities. Frail expects the Kendall Square site to “serve as a portal to [Allergan’s] other R&D sites” in New Jersey, San Francisco and elsewhere.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach